Immuno-oncology
From the Journals
Thoracic cancer approvals differ at FDA, EMA
The EMA had fewer approvals and took longer to make decisions.
Latest News
Adverse events linked to better survival with ICIs in melanoma
“We feel these findings will help clinicians in discussions with patients and in clinical decision-making after adverse events develop,” one of...
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
Conference Coverage
Acetaminophen linked to diminished response to immunotherapy in cancer
“Commonly used medications may have a larger impact on the efficacy and toxicity of immune checkpoint blockade than historically seen with...
From the Journals
Age, skin cancer risks for ICI-induced bullous pemphigoid identified
“It’s harder to understand why a presumably antibody-mediated side effect would be more likely to have that cross-reactivity where the tumor...
From the Journals
New injectable gel can deliver immune cells directly to cancer tumors
The gel “is a really exciting step forward because it can change the delivery of these cells and expand this kind of treatment to other cancers...
Conference Coverage
CAR-T in children branching out to solid tumors
News from the FDA/CDC
FDA approves new indications for pembrolizumab
From the Journals
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
Conference Coverage
Dual immunotherapy goes the distance in MSI-H colorectal cancer
SAN FRANCISCO – At a median follow-up of almost 20 months, combination nivolumab and ipilimumab remained highly active as first-line therapy for...
From the Journals
T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study
About one in three patients had a response, translating into the highest objective response rate seen in a study of unselected sarcoma patients...